Drug recall · April 21, 2021
Cefprozil for Oral Suspension USP recall
Why: Superpotent Drug
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.
- Lots / codes
Lot Numbers: a) F801122, exp. date June 2021; b) F801123, exp. date June 2021; c) F801124, exp. date June 2021
- Quantity
- a) 6,816 bottles; b) 3,960 bottles and c) 7,038 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- March 26, 2021 · Voluntary: Firm initiated
- Classified
- April 12, 2021
- Reported
- April 21, 2021
- Ended
- December 16, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefprozil
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.